Blood test to guide treatment after colon cancer liver surgery
Part of Cancer, Digestive system clinical trials.
This trial studies a blood test (called ctDNA) in people with colon cancer that has spread to the liver and is being removed with curative surgery. The goal is to see how the blood test can help with planning and improving treatment after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent and are able to follow the study plan for its full duration
- You are 18 years or older
- You have confirmed colon (colorectal) cancer
- Your colon/rectum primary tumor and liver metastases (liver spots) are being removed (or are scheduled to be removed) within about 6 months
- Your liver metastases are limited to the liver only (or very small, limited lung spots), and a team says surgery is possible
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks a blood test called circulating tumor DNA to help choose the best time and approach for chemotherapy after colon cancer surgery. It aims to reduce recurrence by identifying people who may benefit from treatment based on changes seen in the blood.
This trial is for people with stage II colon cancer who are not currently getting chemotherapy. It uses a blood test to look for tumor DNA, so doctors can decide if chemotherapy might help prevent the cancer from coming back.
This study uses a simple blood test (liquid biopsy) to look for tiny bits of cancer DNA after surgery for colorectal cancer that spread to the liver. It aims to see if this test can find cancer earlier than standard scans, which may help guide future treatment decisions.
This study uses a simple blood test to detect cancer DNA after surgery for early-stage colon cancer. The goal is to help doctors decide whether chemotherapy is truly needed based on the blood test results, rather than giving it to everyone.
This trial uses a blood test (ctDNA, a sign of cancer cells shedding into the blood) to help guide chemotherapy after surgery to remove colorectal liver metastases. It may help patients get the right chemotherapy plan after their operation, potentially based on whether cancer material is still detectable.
This study uses a simple blood test to monitor tiny pieces of tumor DNA (ctDNA) in people with colorectal cancer that spread to the liver or with liver cancer (HCC), before and after liver surgery or transplant. It aims to help doctors detect cancer return earlier and guide treatment.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.